Hyppää sisältöön
    • FI
    • ENG
  • FI
  • /
  • EN
OuluREPO – Oulun yliopiston julkaisuarkisto / University of Oulu repository
Näytä viite 
  •   OuluREPO etusivu
  • Oulun yliopisto
  • Avoin saatavuus
  • Näytä viite
  •   OuluREPO etusivu
  • Oulun yliopisto
  • Avoin saatavuus
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus : a pilot randomized controlled trial

Siponen, M; Huuskonen, L; Kallio‐Pulkkinen, S; Nieminen, P; Salo, T (2017-03-31)

 
Avaa tiedosto
nbnfi-fe2017120855526.pdf (77.95Kt)
nbnfi-fe2017120855526_meta.xml (42.61Kt)
nbnfi-fe2017120855526_solr.xml (39.32Kt)
Lataukset: 

URL:
https://doi.org/10.1111/odi.12653

Siponen, M
Huuskonen, L
Kallio‐Pulkkinen, S
Nieminen, P
Salo, T
John Wiley & Sons
31.03.2017

Siponen, M et al. Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus : a pilot randomized controlled trial. Oral Diseases (2017) 23, 660–668. http://dx.doi.org/10.1111/odi.12653

https://rightsstatements.org/vocab/InC/1.0/
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved. This is the peer reviewed version of the following article: Oral Diseases (2017) 23, 660–668., which has been published in final form at http://dx.doi.org/10.1111/odi.12653. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
https://rightsstatements.org/vocab/InC/1.0/
doi:https://doi.org/10.1111/odi.12653
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi-fe2017120855526
Tiivistelmä

Abstract

Objective: To carry out a double-blind randomized controlled trial (RCT) to compare the effectiveness of topical tacrolimus (TAC), triamcinolone acetonide (TRI), and placebo (PLA) in symptomatic oral lichen planus (OLP).

Methods: A clinical score (CS, range 0–130) was developed to measure the clinical signs and symptoms of OLP. Twenty-seven OLP patients with a CS of ≥20 were randomly allocated to receive 0.1% TAC ointment (n = 11), 0.1% TRI paste (n = 7), or Orabase® paste as PLA (n = 9) for 3 weeks. If the CS dropped ≥20% (interpreted as response), the patients continued the same medication for another 3 weeks. If the CS dropped <20% or increased (non-response), the patients were switched to TAC for 6 weeks. A 6-month follow-up period ensued. The primary outcome variable was the change in CS from baseline to week 3. In primary outcome analysis, CS values between the treatment arms were compared.

Results: Tacrolimus and TRI were more effective (P = 0.012 and 0.031, respectively) than PLA in reducing the CS at week 3. No difference in the efficacy was noted between TAC and TRI (P = 0.997).

Conclusions: This pilot RCT provides evidence for the effectiveness of TAC and TRI over PLA in the management of OLP.

Kokoelmat
  • Avoin saatavuus [37920]
oulurepo@oulu.fiOulun yliopiston kirjastoOuluCRISLaturiMuuntaja
SaavutettavuusselosteTietosuojailmoitusYlläpidon kirjautuminen
 

Selaa kokoelmaa

NimekkeetTekijätJulkaisuajatAsiasanatUusimmatSivukartta

Omat tiedot

Kirjaudu sisäänRekisteröidy
oulurepo@oulu.fiOulun yliopiston kirjastoOuluCRISLaturiMuuntaja
SaavutettavuusselosteTietosuojailmoitusYlläpidon kirjautuminen